News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

June 6, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2019 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
May 13, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 8, 2019 Apellis Pharmaceuticals Reports First Quarter 2019 Business Update and Financial Results
April 5, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 12, 2019 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 11, 2019 Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
March 7, 2019 Apellis Pharmaceuticals Announces Pricing of Public Offering of Common Stock